{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T05:46:25Z","timestamp":1789623985468,"version":"build-2803163510"},"reference-count":109,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006769","name":"RSF","doi-asserted-by":"publisher","award":["#23-15-00482"],"award-info":[{"award-number":["#23-15-00482"]}],"id":[{"id":"10.13039\/501100006769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CIMB"],"abstract":"<jats:p>Duchenne muscular dystrophy (DMD) is a severe X-linked hereditary disorder caused by pathogenic variants in the DMD gene encoding the dystrophin protein. The absence of functional dystrophin leads to destabilization of the dystrophin-associated glycoprotein complex (DAPC), sarcolemmal damage, and progressive degeneration of muscle fibers. Current therapeutic strategies focus on restoring dystrophin expression using genome editing approaches. Adeno-associated virus (AAV) vectors represent the primary delivery platform due to their strong tropism for muscle tissue, low immunogenicity, and ability to achieve long-term transgene expression. However, the limited packaging capacity of AAV (~4.7 kb) necessitates the use of truncated mini- and micro-dystrophin transgenes as well as compact genome editing systems (SaCas9, NmeCas9, Cas12f, TIGR-Tas, and others). Major challenges include immune responses against the viral capsid and transgene products, as well as the inability to perform repeated administrations. Moreover, the duration of expression is limited by the episomal nature of AAV genomes and their loss during muscle fiber regeneration. Despite substantial progress, unresolved issues concerning safety, immunogenicity, and stability of genetic correction remain, defining the key directions for future research in DMD therapy.<\/jats:p>","DOI":"10.3390\/cimb47121058","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T15:53:46Z","timestamp":1765986826000},"page":"1058","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The Promise and Pitfalls of AAV-Mediated Gene Therapy for Duchenne Muscular Dystrophy"],"prefix":"10.3390","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-2296-2031","authenticated-orcid":false,"given":"Elizaveta V.","family":"Kurshakova","sequence":"first","affiliation":[{"name":"Research Centre for Medical Genetics, 115522 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9465-4213","authenticated-orcid":false,"given":"Olga A.","family":"Levchenko","sequence":"additional","affiliation":[{"name":"Research Centre for Medical Genetics, 115522 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1558-3048","authenticated-orcid":false,"given":"Svetlana A.","family":"Smirnikhina","sequence":"additional","affiliation":[{"name":"Research Centre for Medical Genetics, 115522 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4962-6947","authenticated-orcid":false,"given":"Alexander V.","family":"Lavrov","sequence":"additional","affiliation":[{"name":"Research Centre for Medical Genetics, 115522 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1002\/1097-4598(200010)23:10<1456::AID-MUS2>3.0.CO;2-T","article-title":"Molecular basis of muscular dystrophies","volume":"23","author":"Cohn","year":"2000","journal-title":"Muscle Nerve"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/344064a0","article-title":"Dystrophin gene transcribed from different promoters in neuronal and glial cells","volume":"344","author":"Chelly","year":"1990","journal-title":"Nature"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1093\/hmg\/1.7.505","article-title":"Expression of four alternative dystrophin transcripts in brain regions regulated by different promoters","volume":"1","author":"Monaco","year":"1992","journal-title":"Hum. Mol. Genet."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(02)07815-7","article-title":"The muscular dystrophies","volume":"359","author":"Emery","year":"2002","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1002\/j.2040-4603.2015.tb00638.x","article-title":"The Dystrophin Complex: Structure, Function, and Implications for Therapy","volume":"5","author":"Gao","year":"2015","journal-title":"Compr. Physiol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1083\/jcb.122.4.809","article-title":"A role for the dystrophin-glycoprotein complex as a transmembrane linker between laminin and actin","volume":"122","author":"Ervasti","year":"1993","journal-title":"J. Cell Biol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1038\/s41598-019-39532-4","article-title":"Regulation of the dystrophin-associated glycoprotein complex composition by the metabolic properties of muscle fibres","volume":"9","author":"Omairi","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S1570-9639(02)00442-9","article-title":"New aspects of calcium signaling in skeletal muscle cells: Implications in Duchenne muscular dystrophy","volume":"1600","author":"Gailly","year":"2002","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0301-0082(00)00055-1","article-title":"Safety factor at the neuromuscular junction","volume":"64","author":"Wood","year":"2001","journal-title":"Prog. Neurobiol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1083\/jcb.200905048","article-title":"Dystrophin is a microtubule-associated protein","volume":"186","author":"Prins","year":"2009","journal-title":"J. Cell Biol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1152\/physrev.00007.2015","article-title":"Absence of Dystrophin Disrupts Skeletal Muscle Signaling: Roles of Ca2+, Reactive Oxygen Species, and Nitric Oxide in the Development of Muscular Dystrophy","volume":"96","author":"Allen","year":"2016","journal-title":"Physiol. Rev."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13395-018-0182-x","article-title":"Dystrophin R16\/17-syntrophin PDZ fusion protein restores sarcolemmal nNOS\u03bc","volume":"8","author":"Patel","year":"2018","journal-title":"Skelet. Muscle"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"13818","DOI":"10.1073\/pnas.250379497","article-title":"Functional muscle ischemia in neuronal nitric oxide synthase-deficient skeletal muscle of children with Duchenne muscular dystrophy","volume":"97","author":"Sander","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.stem.2018.03.022","article-title":"The Dystrophin Glycoprotein Complex Regulates the Epigenetic Activation of Muscle Stem Cell Commitment","volume":"22","author":"Chang","year":"2018","journal-title":"Cell Stem Cell"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1152\/physrev.00028.2001","article-title":"Function and genetics of dystrophin and dystrophin-related proteins in muscle","volume":"82","author":"Blake","year":"2002","journal-title":"Physiol. Rev."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Bernardini, C. (2018). Clinical Manifestations and Overall Management Strategies for Duchenne Muscular Dystrophy. Duchenne Muscular Dystrophy: Methods and Protocols, Springer.","DOI":"10.1007\/978-1-4939-7374-3"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1038\/s41467-025-56644-w","article-title":"Duchenne muscular dystrophy: Recent insights in brain related comorbidities","volume":"16","author":"Vaillend","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/humu.22758","article-title":"The TREAT-NMD DMD Global Database: Analysis of more than 7000 Duchenne muscular dystrophy mutations","volume":"36","author":"Bladen","year":"2015","journal-title":"Hum. Mutat."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/0888-7543(88)90113-9","article-title":"An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus","volume":"2","author":"Monaco","year":"1988","journal-title":"Genomics"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.nmd.2008.10.011","article-title":"Dystrophin gene analysis in Hungarian Duchenne\/Becker muscular dystrophy families\u2014Detection of carrier status in symptomatic and asymptomatic female relatives","volume":"19","author":"Nagy","year":"2009","journal-title":"Neuromuscul. Disord."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"18","DOI":"10.17816\/gc641931","article-title":"Challenges in developing gene therapy against Duchenne muscular dystrophy","volume":"20","author":"Kurshakova","year":"2025","journal-title":"Genes Cells"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.4161\/cc.4.10.2114","article-title":"Self-renewal of the adult skeletal muscle satellite cell","volume":"4","author":"Collins","year":"2005","journal-title":"Cell Cycle"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Gaina, G., Budisteanu, M., Manole, E., and Ionica, E. (2019). Clinical and Molecular Diagnosis in Muscular Dystrophies. Muscular Dystrophies, IntechOpen.","DOI":"10.5772\/intechopen.85339"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S0014-5793(98)00251-8","article-title":"Effective restoration of dystrophin-associated proteins in vivo by adenovirus-mediated transfer of truncated dystrophin cDNAs","volume":"425","author":"Yuasa","year":"1998","journal-title":"FEBS Lett."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ymthe.2019.12.010","article-title":"AAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer","volume":"28","author":"Kuranda","year":"2020","journal-title":"Mol. Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1126\/science.149.3685.754","article-title":"Adenovirus-Associated Defective Virus Particles","volume":"149","author":"Atchison","year":"1965","journal-title":"Science"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/sj.gt.3300680","article-title":"Adeno-associated virus vectors can be efficiently produced without helper virus","volume":"5","author":"Matsushita","year":"1998","journal-title":"Gene Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1128\/JVI.72.3.2224-2232.1998","article-title":"Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus","volume":"72","author":"Xiao","year":"1998","journal-title":"J. Virol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1159\/000060327","article-title":"Molecular biology of adeno-associated viruses","volume":"4","author":"Linden","year":"2000","journal-title":"Contrib. Microbiol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"10220","DOI":"10.1073\/pnas.1001673107","article-title":"A viral assembly factor promotes AAV2 capsid formation in the nucleolus","volume":"107","author":"Sonntag","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1126\/science.aaw2900","article-title":"Comprehensive AAV capsid fitness landscape reveals a viral gene and enables machine-guided design","volume":"366","author":"Ogden","year":"2019","journal-title":"Science"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1128\/jvi.34.2.402-409.1980","article-title":"Nucleotide sequence of the inverted terminal repetition in adeno-associated virus DNA","volume":"34","author":"Lusby","year":"1980","journal-title":"J. Virol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"8568","DOI":"10.1128\/JVI.72.11.8568-8577.1998","article-title":"Circular intermediates of recombinant adeno-associated virus have defined structural characteristics responsible for long-term episomal persistence in muscle tissue","volume":"72","author":"Duan","year":"1998","journal-title":"J. Virol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/sj.mt.6300027","article-title":"Design of Tissue-specific Regulatory Cassettes for High-level rAAV-mediated Expression in Skeletal and Cardiac Muscle","volume":"15","author":"Salva","year":"2007","journal-title":"Mol. Ther."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"16105","DOI":"10.1038\/ncomms16105","article-title":"Long-term microdystrophin gene therapy is effective in a canine model of Duchenne muscular dystrophy","volume":"8","author":"Servais","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/nm1085","article-title":"Systemic delivery of genes to striated muscles using adeno-associated viral vectors","volume":"10","author":"Gregorevic","year":"2004","journal-title":"Nat. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"13464","DOI":"10.1073\/pnas.011510597","article-title":"The dystrophin-associated glycoprotein complex: What parts can you do without?","volume":"97","author":"Sweeney","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/343180a0","article-title":"Very mild muscular dystrophy associated with the deletion of 46% of dystrophin","volume":"343","author":"England","year":"1990","journal-title":"Nature"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nm0302-253","article-title":"Modular flexibility of dystrophin: Implications for gene therapy of Duchenne muscular dystrophy","volume":"8","author":"Harper","year":"2002","journal-title":"Nat. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1126\/science.2662404","article-title":"The molecular basis of muscular dystrophy in the mdx mouse: A point mutation","volume":"244","author":"Sicinski","year":"1989","journal-title":"Science"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1093\/hmg\/4.8.1251","article-title":"Expression of full-length and truncated dystrophin mini-genes in transgenic mdx mice","volume":"4","author":"Phelps","year":"1995","journal-title":"Hum. Mol. Genet."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1007\/s40265-023-01929-x","article-title":"Delandistrogene Moxeparvovec: First Approval","volume":"83","author":"Hoy","year":"2023","journal-title":"Drugs"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1001\/jamaneurol.2020.1484","article-title":"Assessment of Systemic Delivery of rAAVrh74.MHCK7.micro-dystrophin in Children with Duchenne Muscular Dystrophy: A Nonrandomized Controlled Trial","volume":"77","author":"Mendell","year":"2020","journal-title":"JAMA Neurol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/s41591-024-03304-z","article-title":"AAV gene therapy for Duchenne muscular dystrophy: The EMBARK phase 3 randomized trial","volume":"31","author":"Mendell","year":"2025","journal-title":"Nat. Med."},{"key":"ref_45","unstructured":"Pfizer (2025, October 24). A Phase 2, Multicenter, Single-Arm Study to Evaluate the Safety and Dystrophin Expression After Fordadistrogene Movaparvovec (PF-06939926) Administration in Male Participants with Early Stage Duchenne Muscular Dystrophy, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05429372."},{"key":"ref_46","unstructured":"Pfizer (2025, October 24). A phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Evaluate The Safety and Efficacy of PF-06939926 for the Treatment of Duchenne Muscular Dystrophy, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04281485."},{"key":"ref_47","unstructured":"Solid Biosciences Inc. (2025, October 29). A Randomized, Controlled, Open-Label, Single-Ascending Dose, Phase I\/II Study to Investigate the Safety and Tolerability, and Efficacy of Intravenous SGT-001 in Male Adolescents and Children with Duchenne Muscular Dystrophy, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03368742."},{"key":"ref_48","unstructured":"Solid Biosciences Inc. (2025, October 29). A Phase 1\/2, Multicenter, Open-Label Study to Investigate the Safety, Tolerability, and Efficacy of a Single Intravenous Dose of SGT-003 in Males with Duchenne Muscular Dystrophy (Inspire Duchenne), Available online: https:\/\/clinicaltrials.gov\/study\/NCT06138639."},{"key":"ref_49","unstructured":"REGENXBIO Inc. (2025, October 30). A Phase 1\/2\/3 Open-Label Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacodynamics, and Pharmacokinetics of Intravenous RGX-202 Gene Therapy in Males with Duchenne Muscular Dystrophy (DMD), Available online: https:\/\/clinicaltrials.gov\/study\/NCT05693142."},{"key":"ref_50","unstructured":"Regenxbio Inc. (2025, October 29). Anti-AAV8 Antibody Assessment Study of Boys with Duchenne Muscular Dystrophy Aged 0 to <12 Years, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05683379."},{"key":"ref_51","unstructured":"(2025, October 29). Clinical Trials Register\u2014Search for 2020-002093-27. Available online: https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=2020-002093-27."},{"key":"ref_52","unstructured":"Insmed Gene Therapy LLC (2025, October 29). A Phase 1, Multicenter, Open-Label Study to Investigate the Safety and Biodistribution of a Single Intrathecal Injection of INS1201 in Ambulatory Males with Duchenne Muscular Dystrophy (The ASCEND Study), Available online: https:\/\/clinicaltrials.gov\/study\/NCT06817382."},{"key":"ref_53","unstructured":"Adu-Gyamfi, E. (2023). Summary Basis for Regulatory Action."},{"key":"ref_54","unstructured":"(2025, October 24). Protocol C3391001\u2014A Phase 1b Multicenter, Open-Label, Single Ascending Dose Study to Evaluate the Safety and Tolerability of Fordadistrogene Movaparvovec (PF-06939926) in Ambulatory and Non-Ambulatory Subjects with Duchenne Muscular Dystrophy, Available online: https:\/\/cdn.clinicaltrials.gov\/large-docs\/02\/NCT03362502\/SAP_001.pdf."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"S188","DOI":"10.1016\/j.nmd.2017.06.343","article-title":"SGT-001 Micro-dystrophin gene therapy for Duchenne muscular dystrophy","volume":"27","author":"Schneider","year":"2017","journal-title":"Neuromuscul. Disord."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"101519","DOI":"10.1016\/j.omtm.2025.101519","article-title":"Enhanced therapeutic potential of a microdystrophin with an extended C-terminal domain","volume":"33","author":"Foltz","year":"2025","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_57","unstructured":"(2025, October 30). Genethon to Launch Pivotal Trial in Europe of GNT0004 a Low-Dose Microdystrophin Gene Therapy for Duchenne Muscular Dystrophy. G\u00e9n\u00e9thon. Available online: https:\/\/www.genethon.com\/genethon-to-launch-pivotal-trial-in-europe-of-gnt0004-a-low-dose-microdystrophin-gene-therapy-for-duchenne-muscular-dystrophy\/."},{"key":"ref_58","unstructured":"(2025, October 30). WO 2023\/015304 A1. Available online: https:\/\/patentimages.storage.googleapis.com\/17\/27\/e5\/f679ee10f0222e\/AU2022325165A1.pdf."},{"key":"ref_59","unstructured":"Sarepta Therapeutics, Inc. (2025, October 24). A Phase 3 Multinational, Randomized, Double-Blind, Placebo-Controlled Systemic Gene Delivery Study to Evaluate the Safety and Efficacy of SRP-9001 in Subjects with Duchenne Muscular Dystrophy (EMBARK), Available online: https:\/\/clinicaltrials.gov\/study\/NCT05096221."},{"key":"ref_60","unstructured":"(2025, October 29). DMD Program Discontinuation PAG Letter Final. Available online: https:\/\/cureduchenne.org\/wp-content\/uploads\/2024\/07\/DMD-Program-Discontinuation-PAG-Letter_Final.pdf."},{"key":"ref_61","unstructured":"(2025, October 30). RGX-202. Available online: https:\/\/www.regenxbio.com\/therapeutic-programs\/rgx-202\/."},{"key":"ref_62","unstructured":"(2025, October 30). Insmed Provides Business Update at 43rd Annual, J.P. Morgan Healthcare Conference. Available online: https:\/\/investor.insmed.com\/2025-01-10-Insmed-Provides-Business-Update-at-43rd-Annual-J-P-Morgan-Healthcare-Conference?utm_source=chatgpt.com."},{"key":"ref_63","unstructured":"(2025, October 24). FDA Requests Sarepta Therapeutics Suspend Distribution of Elevidys and Places Clinical Trials on Hold for Multiple Gene Therapy Products Following 3 Deaths, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-requests-sarepta-therapeutics-suspend-distribution-elevidys-and-places-clinical-trials-hold."},{"key":"ref_64","unstructured":"Stansfield, N. (2025, October 24). New Death of Patient Treated with Sarepta\u2019s Elevidys Being Investigated by FDA, but Company Claims It Is Unrelated to the Therapy|CGTlive\u00ae. Available online: https:\/\/www.cgtlive.com\/view\/new-death-patient-treated-sarepta-elevidys-being-investigated-fda-company-claims-unrelated-therapy."},{"key":"ref_65","unstructured":"Stansfield, N. (2025, October 24). FDA Announces Investigation of Deaths Following Treatment with Sarepta\u2019s DMD Gene Therapy Elevidys|CGTlive\u00ae. Available online: https:\/\/www.cgtlive.com\/view\/fda-announces-investigation-deaths-following-treatment-sarepta-dmd-gene-therapy-elevidys."},{"key":"ref_66","unstructured":"(2025, October 29). DMD Study 1001 Update Letter to the Community. Available online: https:\/\/www.parentprojectmd.org\/wp-content\/uploads\/2021\/12\/DMD-Study-1001-Update_Letter-to-the-Community.pdf."},{"key":"ref_67","unstructured":"Masson, G. (2025, October 29). Young Participant in Pfizer\u2019s DMD Gene Therapy Trial Dies. Available online: https:\/\/www.fiercebiotech.com\/biotech\/pfizer-reports-death-young-boy-dmd-who-participated-gene-therapy-trial."},{"key":"ref_68","unstructured":"Solid Biosciences Inc. (2025, October 29). Solid Biosciences Reports Positive Initial Clinical Data from Next-Generation Duchenne Gene Therapy Candidate SGT-003. Available online: https:\/\/investors.solidbio.com\/news-releases\/news-release-details\/solid-biosciences-reports-positive-initial-clinical-data-next."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1089\/hum.1996.7.17-2101","article-title":"Quantitative analysis of the packaging capacity of recombinant adeno-associated virus","volume":"7","author":"Dong","year":"1996","journal-title":"Hum. Gene Ther."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1126\/science.aad5177","article-title":"In vivo gene editing in dystrophic mouse muscle and muscle stem cells","volume":"351","author":"Tabebordbar","year":"2016","journal-title":"Science"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.molcel.2018.12.003","article-title":"A compact, high-accuracy Cas9 with a dinucleotide PAM for in vivo genome editing","volume":"73","author":"Edraki","year":"2019","journal-title":"Mol. Cell"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ymthe.2021.05.010","article-title":"Single AAV-mediated CRISPR-Nme2Cas9 efficiently reduces mutant hTTR expression in a transgenic mouse model of transthyretin amyloidosis","volume":"30","author":"Wen","year":"2022","journal-title":"Mol. Ther."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"14500","DOI":"10.1038\/ncomms14500","article-title":"In vivo genome editing with a small Cas9 orthologue derived from Campylobacter jejuni","volume":"8","author":"Kim","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Wang, H., Zhou, J., Lei, J., Mo, G., Wu, Y., Liu, H., Pang, Z., Du, M., Zhou, Z., and Paek, C. (2024). Engineering of a compact, high-fidelity EbCas12a variant that can be packaged with its crRNA into an all-in-one AAV vector delivery system. PLoS Biol., 22.","DOI":"10.1371\/journal.pbio.3002619"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41587-021-01009-z","article-title":"Efficient CRISPR editing with a hypercompact Cas12f1 and engineered guide RNAs delivered by adeno-associated virus","volume":"40","author":"Kim","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1126\/science.abb1400","article-title":"CRISPR-Cas\u03a6 from huge phages is a hypercompact genome editor","volume":"369","author":"Pausch","year":"2020","journal-title":"Science"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"eadv9789","DOI":"10.1126\/science.adv9789","article-title":"TIGR-Tas: A Family of Modular RNA-Guided DNA-Targeting Systems in Prokaryotes and Their Viruses","volume":"388","author":"Faure","year":"2025","journal-title":"Science"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1146\/annurev-bioeng-071813-104938","article-title":"Viral Vectors for Gene Therapy: Translational and Clinical Outlook","volume":"17","author":"Kotterman","year":"2015","journal-title":"Annu. Rev. Biomed. Eng."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1056\/NEJMoa2113708","article-title":"Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A","volume":"386","author":"Ozelo","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"S303","DOI":"10.3233\/JND-210678","article-title":"Gene Therapy for Duchenne Muscular Dystrophy","volume":"8","author":"Elangkovan","year":"2021","journal-title":"J. Neuromuscul. Dis."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"10","DOI":"10.17650\/2222-8721-2023-13-2-10-19","article-title":"Consensus concept of modern effective therapy for Duchenne muscular dystrophy","volume":"13","author":"Gremyakova","year":"2023","journal-title":"Neuromuscul. Dis."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1016\/j.ymthe.2018.07.011","article-title":"Systemic AAV Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy","volume":"26","author":"Duan","year":"2018","journal-title":"Mol. Ther."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3233\/JND-221639","article-title":"Meeting Report: 2022 Muscular Dystrophy Association Summit on \u201cSafety and Challenges in Gene Transfer Therapy\u201d","volume":"10","author":"Lek","year":"2023","journal-title":"J. Neuromuscul. Dis."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/hematology.2019000007","article-title":"Gene therapy for hemophilia","volume":"2019","author":"Nathwani","year":"2019","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1056\/NEJMoa1108046","article-title":"Adenovirus-Associated Virus Vector\u2013Mediated Gene Transfer in Hemophilia B","volume":"365","author":"Nathwani","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Ronzitti, G., Gross, D.A., and Mingozzi, F. (2020). Human Immune Responses to Adeno-Associated Virus (AAV) Vectors. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.00670"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1542\/peds.2018-0333E","article-title":"Bone Health and Osteoporosis Management of the Patient with Duchenne Muscular Dystrophy","volume":"142","author":"Ward","year":"2018","journal-title":"Pediatrics"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"e1312","DOI":"10.1212\/WNL.0000000000008168","article-title":"Vamorolone trial in Duchenne muscular dystrophy shows dose-related improvement of muscle function","volume":"93","author":"Hoffman","year":"2019","journal-title":"Neurology"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"6381","DOI":"10.1128\/JVI.78.12.6381-6388.2004","article-title":"Clades of Adeno-associated viruses are widely disseminated in human tissues","volume":"78","author":"Gao","year":"2004","journal-title":"J. Virol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1128\/CVI.05107-11","article-title":"Adeno-Associated Virus Antibody Profiles in Newborns, Children, and Adolescents","volume":"18","author":"Calcedo","year":"2011","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1093\/hmg\/5.11.1703","article-title":"Immunology of Gene Therapy with Adenoviral Vectors in Mouse Skeletal Muscle","volume":"5","author":"Yang","year":"1996","journal-title":"Hum. Mol. Genet."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1089\/hum.2009.182","article-title":"Prevalence of Serum IgG and Neutralizing Factors Against Adeno-Associated Virus (AAV) Types 1, 2, 5, 6, 8, and 9 in the Healthy Population: Implications for Gene Therapy Using AAV Vectors","volume":"21","author":"Boutin","year":"2010","journal-title":"Hum. Gene Ther."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/j.ymthe.2020.06.001","article-title":"Long-Term Follow-Up of the First in Human Intravascular Delivery of AAV for Gene Transfer: AAV2-hFIX16 for Severe Hemophilia B","volume":"28","author":"George","year":"2020","journal-title":"Mol. Ther."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1182\/blood-2005-08-3229","article-title":"Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID mice","volume":"107","author":"Scallan","year":"2006","journal-title":"Blood"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/mt.2013.244","article-title":"Plasmapheresis eliminates the negative impact of AAV antibodies on microdystrophin gene expression following vascular delivery","volume":"22","author":"Chicoine","year":"2014","journal-title":"Mol. Ther."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1128\/JVI.74.3.1524-1532.2000","article-title":"Repeat transduction in the mouse lung by using adeno-associated virus vectors with different serotypes","volume":"74","author":"Halbert","year":"2000","journal-title":"J. Virol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1056\/NEJMoa2307798","article-title":"Death after High-Dose rAAV9 Gene Therapy in a Patient with Duchenne\u2019s Muscular Dystrophy","volume":"389","author":"Lek","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1016\/j.ymthe.2023.10.015","article-title":"Lethal immunotoxicity in high-dose systemic AAV therapy","volume":"31","author":"Duan","year":"2023","journal-title":"Mol. Ther."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1089\/hum.2024.179","article-title":"Current and Emerging Issues in Adeno-Associated Virus Vector-Mediated Liver-Directed Gene Therapy","volume":"36","author":"Piccolo","year":"2025","journal-title":"Hum. Gene Ther."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1056\/NEJMc2212912","article-title":"Dystrophin Immunity after Gene Therapy for Duchenne\u2019s Muscular Dystrophy","volume":"388","author":"Belluscio","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJMoa1000228","article-title":"Dystrophin immunity in Duchenne\u2019s muscular dystrophy","volume":"363","author":"Mendell","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_104","unstructured":"(2025, October 29). Package Insert\u2014ELEVIDYS, Available online: https:\/\/www.fda.gov\/media\/184855\/download?attachment."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/s41591-018-0326-x","article-title":"Identification of preexisting adaptive immunity to Cas9 proteins in humans","volume":"25","author":"Charlesworth","year":"2019","journal-title":"Nat. Med."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1038\/s41467-019-09693-x","article-title":"Multifunctional CRISPR-Cas9 with engineered immunosilenced human T cell epitopes","volume":"10","author":"Ferdosi","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1146\/annurev-med-081117-010451","article-title":"CRISPR Correction of Duchenne Muscular Dystrophy","volume":"70","author":"Min","year":"2019","journal-title":"Annu. Rev. Med."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"14038","DOI":"10.1038\/mtm.2014.38","article-title":"Adeno-associated viral (AAV) vectors do not efficiently target muscle satellite cells","volume":"1","author":"Arnett","year":"2014","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"3834","DOI":"10.1039\/D3NA00198A","article-title":"Strategies for targeted gene delivery using lipid nanoparticles and cell-derived nanovesicles","volume":"5","author":"Lee","year":"2023","journal-title":"Nanoscale Adv."}],"container-title":["Current Issues in Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1467-3045\/47\/12\/1058\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T08:55:58Z","timestamp":1766134558000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1467-3045\/47\/12\/1058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,17]]},"references-count":109,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["cimb47121058"],"URL":"https:\/\/doi.org\/10.3390\/cimb47121058","relation":{},"ISSN":["1467-3045"],"issn-type":[{"value":"1467-3045","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,17]]}}}